Drug intelligence / Profile preview

BPR002

Development stage: Unknown
Lead developer: BiPER Therapeutics
Modality: Small Molecules

Overview

BPR002 is a small molecule drug initially developed by Biper Therapeutics SAS. It is currently in the discovery phase of research and development. The drug is being investigated primarily for therapeutic areas including neoplasms (cancers) and skin and musculoskeletal diseases, with an active indication focus on melanoma. The exact mechanism of action has not been detailed publicly, but it is associated with targeting cancer-related pathways, potentially involving GRP78 inhibition as suggested by related research interests at Biper Therapeutics SAS. This target is implicated in cancer cell survival and progression, making it a novel approach in oncology treatment development.

Other names: BPR002BPR-002BPR 002

Targets

HSPA5 (Heat shock protein family A member 5)

Beyond the preview

Go deeper on BPR002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPR002.

Explore the full profile